CNS: Sex steroids and SERMs

Annals of the New York Academy of Sciences

Volumn 997, Issue , 2003, Pages 378-388

  Bernardi, F ^a   Pluchino, N ^a   Stomati, M ^a   Pieri, M ^a   Genazzani, A R ^a  

^a UNIVERSITY OF PISA   (Italy)

Author keywords

Allopregnanolone; Beta endorphin; Central nervous system (CNS); DHEA; Neurosteroids; Selective estrogen receptor modulator (SERMs); Sex steroids

Indexed keywords

3ALPHA HYDROXY 5ALPHA PREGNAN 20 ONE; 4 AMINOBUTYRIC ACID A RECEPTOR BLOCKING AGENT; 4 AMINOBUTYRIC ACID A RECEPTOR STIMULATING AGENT; 6 HYDROXY 2 (4 HYDROXYPHENYL) 3 [4 [2 (1 PYRROLIDINYL)ETHOXY]BENZOYL]BENZO[B]THIOPHENE; ACOLBIFENE; ANTIESTROGEN; BETA ENDORPHIN; CONJUGATED ESTROGEN; EM 625; ESTRADIOL; ESTRADIOL VALERATE; ESTROGEN; NEUROPEPTIDE; NEUROSTEROID; NEUROTRANSMITTER; NOMEGESTROL; NORETHISTERONE ACETATE; PRASTERONE; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; SEX HORMONE; TAMOXIFEN; UNCLASSIFIED DRUG;

BRAIN FUNCTION; CENTRAL NERVOUS SYSTEM; COGNITION; CONFERENCE PAPER; DRUG ACTIVITY; DRUG EFFECT; EXCITABILITY; HUMAN; MOOD; NEUROENDOCRINOLOGY; NEUROTRANSMITTER RELEASE; NONHUMAN; OVARIECTOMY; POSTMENOPAUSE; PROTEIN METABOLISM; STEROIDOGENESIS; SYNAPSE; AGED; ANIMAL; ANIMAL MODEL; BRAIN; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; FEMALE; FOLLOW UP; MIDDLE AGED; NEUROSECRETION; PHYSIOLOGY; RANDOMIZED CONTROLLED TRIAL; RAT; REVIEW; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY;

AGED; ANIMALS; BRAIN; CENTRAL NERVOUS SYSTEM; FEMALE; FOLLOW-UP STUDIES; HUMANS; MIDDLE AGED; MODELS, ANIMAL; NEUROSECRETORY SYSTEMS; POSTMENOPAUSE; RANDOMIZED CONTROLLED TRIALS; RATS; RISK ASSESSMENT; SELECTIVE ESTROGEN RECEPTOR MODULATORS; SENSITIVITY AND SPECIFICITY;

EID: 0642364487     PISSN: 00778923     EISSN: None     Source Type: Book Series    
DOI: 10.1196/annals.1290.041     Document Type: Conference Paper

References (56)

1. SPEROFF, L., R.H. GLASS & N.H. KASE, Eds., 1995. Clinical Gynecological Endocrinology and Infertility, 5th ed. Williams and Wilkins. Baltimore, MD.
2. PAECH, K., P. WEBB, G.G. KUIPER, et al. 1997. Differential ligand activation of estrogen receptors ERalpha and ERbeta at AP1 sites. Science 277: 1508-1510.
3. LABRIE, F., C. LABRIE, A. BELANGER, et al. 2001. Pure selective estrogen receptor modulators, new molecules having absolute cell specificity ranging from pure antiestrogenic to complete estrogen-like activities. Adv. Protein Chem. 56: 293-368.
4. ALONSO-SOLEIS, R., P. ABREU, I. LEOPEZ-COVIELLA, et al. 1996. Gonadal steroid modulation of neuroendocrine transduction: a transynaptic view. Cell. Mol. Neurobiol. 3: 357-382.
5. COUSE, J.F., J. LINDZEY, K. GRANDIEN, et al. 1997. Tissue distribution and quantitative analysis of estrogen receptor-alpha (ERalpha) and estrogen receptor-beta (ERbeta) messenger ribonucleic acid in the wild-type and ERalpha-knockout mouse. Endocrinology 138: 4613-4621.
6. WONG, M., T.L. THOMPSON, R.L. MOSS. 1996. Nongenomic actions of estrogen in the brain: physiological significance and cellular mechanisms. Crit. Rev. Neurobiol. 10: 189-203.
7. KELLY, M.J., A.H. LAGRANGE, E.J. WAGNHI & O.K. RONNEKLEIV. 1999. Rapid effects of estrogen to modulate G protein-coupled receptors via activation of protein kinase A and protein kinase C pathways. Steroids 64: 64-75.
8. LEVIN, E.R. 1999. Cellular Functions of the Plasma Membrane Estrogen Receptor. Trends Endocrinol. Metab. 10: 374-377.
9. DICKINSON, S.L. & G. CURZON. 1986. 5-Hydroxytryptamine-mediated behavior in male and female rats. Neuropharmacology 25: 771-776.
10. BIEGON, A., H. BERCOVITZ & D. SAMUEL. 1980. Serotonin receptor concentration during the estrous cycle of the rat. Brain Res. 187: 221-225.
11. 3H)-paroxetine binding into the cerebral cortex and dorsal hippocampus of gonadectomized male and female rats. Brain Res. 601: 299-301.
12. BETHEA, C.L., S.J. MIRKES, A. SU & D. MICHELSON. 2002. Effects of oral estrogen, raloxifene and arzoxifene on gene expression in serotonin neurons of macaques. Psychoneuroendocrinology 27: 431-445.
13. LUINE, V.N. & B.S. MCEWEN. 1977. Effect of estradiol on turnover of Type A monoamine oxidase in the brain. J. Neurochem. 28: 1221-1227.
14. BETHEA, C.L., N.Z. Lu, C. GUNDLAH & J.M. STREICHER. 2002. Diverse actions of ovarian steroids in the serotonin neural system. Front. Neuroendocrinol. 23: 41-100.
15. CYR, M., M. LANDRY & T. Di PAOLO. 2000. Modulation by estrogen-receptor directed drugs of 5-hydroxytryptamine-2A receptors in rat brain. Neuropsychopharmacology 23: 69-78.
16. GUNDLAH, C., S.G. KOHAMA, S.J. MIRKES, et al. 2000. Distribution of estrogen receptor beta (ERbeta) mRNA in hypothalamus, midbrain and temporal lobe of spayed macaque: continued expression with hormone replacement. Brain Res. Mol. Brain Res. 76: 91-204.
17. MONTGOMERY, J.C., L, BRINCAT M, VIRSI, et al. 1987. Effect of oestrogen and test-osterone implants on psychological disorders in the climacteric. Lancet 1: 297-299.
18. LIMOUZIN-LAMOTHE, M.A., N. MAIRON, C.R. JOYCE. & M. LE GAL. 1994. Quality of life after the menopause: influence of hormonal replacement therapy. Am. J. Obstet. Gynecol. 170: 618-624.
19. KARLA, S.P. 1996. Gonadal steroid hormones promote interactive comunication. In The Brain: Source and Target for Sex Steroid Hormones. A.R. Genazzani, F. Petraglia, and R.H. Purdy. Eds.: 257-276. Parthenon Publishing Group. London.
20. LANDRY, M., D. LEVESQUE & T. DI PAOLO. 2002. Estrogenic properties of raloxifene, but not tamoxifen, on d(2) and d(3) dopamine receptors in the rat forebrain. Neuroendocrinology 76: 214-22.
21. TORAN-ALLERAND, C.D. 1996. The estrogen/neurotrophin connection during neu-raldevelopment: is co-localization of estrogen receptors with the neurotrophins and their receptors biologically relevant? Dev. Neurosci. 18: 36-48.
22. MCMILLAN, P.J., C.A. SINGER &D.M. DORSA. 1996. The effects of ovariectomy andestrogen replacement on trkA and choline acetyltransferase mRNA expression in the basal forebrain of the adult female Sprague-Dawley rat. J. Neurosci. 16: 1860-1865.
23. MCMILLAN, P.J., A.M. LEMASTER &D.M. DORSA. 2002. Tamoxifen enhances choline acetyltransferase mRNA expression in rat basal forebrain cholinergic neurons. Brain Res. Mol. Brain Res. 103: 140-145.
24. PAGANINI-HILL, A. & L.J. CLARK. 2000. Preliminary assessment of cognitive function in breast cancer patients treated with tamoxifen. Breast Cancer Res. Treat. 64: 165-176.
25. YAFFE, K., K. KRUEGER, S. SARKAR, et al. 2001. Cognitive function in postmenopausal women treated with raloxifene. N. Engl. J. Med. 344: 1207-1213.
26. GENAZZANI, A.R., F. PETRAGLIA, F. FACCHTNETTI, et al. 1988. Steroid replacement increase beta-endorphin and beta-lipotropin plasma levels in postmenopausal women. Gynecol. Obstet. Invest. 26: 153-159.
27. ALEEM, F.A. & T. MCITOSH. 1985. Menopausal syndrome: plasma levels of β-endorphin in postmenopausal women using a specific radioimmunoassay. Maturitas 13: 76-84.
28. GENAZZANI, A.R., F. PETRAGLIA, F. FACCHINETTI, et al. 1984. Increase of proopiomelanocortin-related peptides during subjective menopausal flushes. Am. J. Obstet. Gynecol. 149: 775-779.
29. LINGHTMAN, S.L., H.S. JACOBS, A.K. MAGUIRE, et al. 1981. Climateric flushing: clinical and endocrine response to infusion of naloxone. Br. J. Obstet. Gynecol. 88: 919-924.
30. GENAZZANI, A.R., F. PETRAGLIA, M. CLEVA, et al. 1989. Norgestimate increases pituitary and hypothalamic concentrations of immunoreactive beta-endorphin. Contraception 5: 605-613.
31. GENAZZANI, A.R., F. PETRAGLIA, N. MERCURI, et al. 1990. Effect of steroid hormones and antihormones on hypothalamic beta-endorphin concentrations in intact and castrated female rats. J. Endocrinol. Invest. 13: 91-96.
32. GENAZZANI, A.R., F. BERNARDI, M. STOMATI, et al. 1999. Raloxifene analog LY 117018 effects on central and peripheral beta-endorphin. Gynecol. Endocrinol. 13: 249-258.
33. FLORIO, P., B. QUIRICI, E. CASAROSA, et al. 2001. Neuroendocrine effects of raloxifene hydrochloride in postmenopausal women. Gynecol. Endocrinol. 15: 359-366.
34. STOMATI, M., P. MONTELEONE, E. CASAROSA, et al. 2000. Six-month oral dehydroepiandrosterone supplementation in early and late postmenopause. Gynecol. Endocrinol. 14: 342-363.
35. PINILLA, L., L.C. GONZALEZ, M. TENA-SEMPERE & E. AGUILAR. 2001. Evidence for an estrogen-like action of raloxifene upon the hypothalamic- pituitary unit: raloxifene inhibits luteinizing hormone secretion and stimulates prolactin secretion in ovariectomized female rats. Neurosci. Lett. 311: 149-152.
36. BERNARDI, F., M. STOMATI, S. LUISI, et al. 2002. Effects of the new generation selective estrogen receptor modulator EM-652 and oral administration of estradiol valerate on circulating, brain, and adrenal beta-endorphin and allopregnanolone levels in intact fertile and ovariectomized rats. Fertil. Steril. 77: 1018-1027.
37. PELLETIER, G., M. EL-ALFY, C. LABRIE, et al. 2001. Effect of long-term treatment with the antiestrogen EM-652.HCl on pituitary estrogen receptor alpha and prolactin mRNA expression in intact, ovariectomized and gonadotropin- releasing hormone-treated female rats. Neuroendocrinology 74: 367-374.
38. PINILLA, L., M.L. BARREIRO, M. TENA-SEMPERE & E. AGUILAR. 2002. Raloxifene effects upon the neuronal system controlling sexual receptivity in female rats. Neurosci. Lett. 329: 285-288.
39. PINILLA, L., M.L. BARREIRO, L.C. GONZALEZ, et al. 2002. Comparative effects of testosterone propionate, oestradiol benzoate, ICI 182,780, tamoxifen and raloxifene on hypothalamic differentiation in the female rat. J. Endocrinol. 172: 441-448.
40. MELLON, S.H. 1994. Neurosteroids: action and clinical relevance. J. Clin. Endocrinol. & Metab. 78: 1003-1008.
41. MAJEWSKA, M.D. 1992. Neurosteroids: endogenous bimodal modulators of the GABA A receptors. Mechanism of action and physiological significance. Prog. Neurobiol. 38: 379-395.
42. WOLF, O.T., O. NEUMENM, D.H. HELHAMMER, et al. 1997. Effects of a two-week physiological dehydroepiandrosterone substitution on cognitive performance and well-being in healthy elderly women and men. J. Clin. Endocrinol. Metab. 82: 2363-2367.
43. MONTELEONE, P., S. LUISI, A. TONETTI, et al. 2000. Allopregnanolone concentrations and premenstrual syndrome. Eur. J. Endocrinol. 142: 269-273.
44. PALUMBO, M.A., C. SALVESTRONI, R. GALLO, et al. 1995. Allopregnanolone concentrations in hippocampus of prepubertal rats and female rats throughout estrous cycle. J. Endocrinol. Invest. 18: 853-856.
45. GENAZZANI, A.R., F. PETRAGLIA, F. BERNARDI, et al. 1998. Circulating levels of allopregnanolone in humans: gender, age and endocrine influences. J. Clin. Endocrinol. Metab. 83: 2099-2103.
46. GENAZZANI, A.R., F. BERNARDI, M. STOMATI, et al. 2000. Effects of estradiol and raloxifene analog on brain, adrenal and serum allopregnanolone content in fertile and ovariectomized female rats. Neuroendocrinology 72: 162-170.
47. SCHUMACHER, M., H. COIRINI, F. ROBERT, et al. 1999. Genomic and membrane actions of progesterone: implications for reproductive physiology and behavior. Behav. Brain Res. 105: 37-52.
48. YAMAJI, T. & H. IBAYASHI. 1969. Serum deydroepiandrosterone sulphate in normal and pathological conditions. J. Clin. Endocrinol. Metab. 29: 273-278.
49. MAJEWSKA, M.D., S. DEMIRGOREN, C.E. SPIVAK, et al. 1990. The neurosteroid DHEA is an allosteric antagonist of the GABA A receptor. Brain Res. 526: 143-146.
50. BAULIEU, E.E. 1996. Dehydroepiandrosterone: a fountain of youth? J. Clin. Endocrinol. & Metab. 81: 3147-3151.
51. THUSSEN, J.H. & H. NIEUWENHUYSE. 1999. DHEA: a comprehensive review. Parthenon. London.
52. RUBINO, S., M. STOMATI, C. BERSI, et al. 1998. Neuroendocrine effect of a short-term treatment with DHEA in postmenopausal women. Maturitas 28: 251-257.
53. TAELMAN, P., J.M. KAYMAN, X. JANSSENS, et al. 1989. Persistence of increased bone-resumption and possible role of dehydroepiandrosterone as a bone metabolism determinant in osteoporotic women in late menopause. Maturitas 11: 65-73.
54. NORDIN, B.E.C., A. ROBERTSON & R.F. SEAMARK. 1985. The relation between calcium absorption, serum DHEA and vertebral mineral density in postmenopausal women. J. Clin. Endocrinol. & Metab. 60: 651-657.
55. WOLKOWITZ, O.M., V.I. REUS, E. ROBERTS, et al. 1997. Dehydroepiandrosterone (DHEA) treatment of depression. Biol. Psychiatry. 41: 311-318.
56. NILSEN, J., G. MOR & F. NAFTOLIN. 1998. Raloxifene induces neunte outgrowth in estrogen receptor positive PC12 cells. Menopause 5: 211-216.